CDK6 Degradation Is Counteracted by p16<sup>INK4A</sup> and p18<sup>INK4C</sup> in AML

CDK6 Degradation Is Counteracted by p16<sup>INK4A</sup> and p18<sup>INK4C</sup> in AML

Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by primary and secondary resistance mechanisms. CDK4/...

Full description

Bibliographic Details
Main Authors: Belinda S. Schmalzbauer, Teresemary Thondanpallil, Gerwin Heller, Alessia Schirripa, Clio-Melina Sperl, Isabella M. Mayer, Vanessa M. Knab, Sofie Nebenfuehr, Markus Zojer, André C. Mueller, Frédéric Fontaine, Thorsten Klampfl, Veronika Sexl, Karoline Kollmann
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
CDK6
AML
degrader
INK4
p16
p18
Online Access:https://www.mdpi.com/2072-6694/14/6/1554

Internet

https://www.mdpi.com/2072-6694/14/6/1554

Similar Items